FDA clears Elscint's TransACT protocol

Article

Elscint has received 510(k) clearance for its TransACT attenuation-correctiontechnique for the CardiaL 90° dual-head gamma camera. Clinicianshave been testing TransACT at Duke University Medical Center inDurham, NC, for its ability to correct

Elscint has received 510(k) clearance for its TransACT attenuation-correctiontechnique for the CardiaL 90° dual-head gamma camera. Clinicianshave been testing TransACT at Duke University Medical Center inDurham, NC, for its ability to correct inferior wall artifactscommon in myocardial imaging with thallium. The company is planningto adapt the technique for the adjustable-angle Varicam cameraas well.

Elscint also announced this month that it has received clearancefor its 2-tesla Prestige MRI scanner.

Recent Videos
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Related Content
© 2025 MJH Life Sciences

All rights reserved.